Recurrence Score Testing Does Not Appear to Benefit Patients with Grade 1, Progesterone Receptor-Positive Breast Cancers: an Opportunity to Eliminate Overtreatment and Decrease Testing Costs.
Hematology/Oncology and Stem Cell Therapy（2021）
关键词
21-gene genomic assay,Breast cancer,Oncotype DX,Overtreatment,Prognosis
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要